Literature DB >> 27604243

Beneficial Effects of a CaMKIIα Inhibitor TatCN21 Peptide in Global Cerebral Ischemia.

Mohammad Ejaz Ahmed1, Yan Dong1, Yujiao Lu1, Donovan Tucker1, Ruimin Wang1, Quanguang Zhang2.   

Abstract

Aberrant calcium influx is a common feature following ischemic reperfusion (I/R) in transient global cerebral ischemia (GCI) and causes delayed neuronal cell death in the CA1 region of the hippocampus. Activation of calcium-calmodulin (CaM)-dependent protein kinase IIα (CaMKIIα) is a key event in calcium signaling in ischemic injury. The present study examined the effects of intracerebroventricular (icv) injection of tatCN21 in ischemic rats 3 h after GCI reperfusion. Cresyl violet and NeuN staining revealed that tatCN21 exerted neuroprotective effects against delayed neuronal cell death of hippocampal CA1 pyramidal neurons 10 days post-GCI. In addition, TatCN21 administration ameliorated GCI-induced spatial memory deficits in the Barnes maze task as well as anxiety-like behaviors and spontaneous motor activity in the elevated plus maze and open field test, respectively. Mechanistic studies showed that the administration of tatCN21 decreased GCI-induced phosphorylation, translocation, and membrane targeting of CaMKIIα. Treatment with tatCN21 also inhibited the level of CaMKIIα-NR2B interaction and NR2B phosphorylation. Our results revealed an important role of tatCN21 in inhibiting CaMKIIα activation and its beneficial effects in neuroprotection and memory preservation in an ischemic brain injury model.

Entities:  

Keywords:  CaMKIIα; Global cerebral ischemia; Hippocampus; NR2B; TatCN21

Mesh:

Substances:

Year:  2016        PMID: 27604243      PMCID: PMC5219940          DOI: 10.1007/s12031-016-0830-8

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  43 in total

Review 1.  Selective vulnerability of the hippocampus in brain ischemia.

Authors:  R Schmidt-Kastner; T F Freund
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

2.  Characterization of a calmodulin kinase II inhibitor protein in brain.

Authors:  B H Chang; S Mukherji; T R Soderling
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

3.  Neuroprotective and Functional Improvement Effects of Methylene Blue in Global Cerebral Ischemia.

Authors:  Qing Lu; Donovan Tucker; Yan Dong; Ningjun Zhao; Quanguang Zhang
Journal:  Mol Neurobiol       Date:  2015-10-03       Impact factor: 5.590

4.  Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor.

Authors:  Rebekah S Vest; Heather O'Leary; Steven J Coultrap; Mark S Kindy; K Ulrich Bayer
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

Review 5.  CaMKII in cerebral ischemia.

Authors:  Steven J Coultrap; Rebekah S Vest; Nicole M Ashpole; Andy Hudmon; K Ulrich Bayer
Journal:  Acta Pharmacol Sin       Date:  2011-06-20       Impact factor: 6.150

6.  Role of the CaMKII/NMDA receptor complex in the maintenance of synaptic strength.

Authors:  Magdalena Sanhueza; German Fernandez-Villalobos; Ivar S Stein; Gyulnara Kasumova; Peng Zhang; K Ulrich Bayer; Nikolai Otmakhov; Johannes W Hell; John Lisman
Journal:  J Neurosci       Date:  2011-06-22       Impact factor: 6.167

7.  CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage.

Authors:  Isabelle Buard; Steven J Coultrap; Ronald K Freund; Yong-Seok Lee; Mark L Dell'Acqua; Alcino J Silva; K Ulrich Bayer
Journal:  J Neurosci       Date:  2010-06-16       Impact factor: 6.167

8.  Calcium/calmodulin-dependent protein kinase II activity in focal ischemia with reperfusion in rats.

Authors:  S K Hanson; J C Grotta; M N Waxham; J Aronowski; P Ostrow
Journal:  Stroke       Date:  1994-02       Impact factor: 7.914

9.  Dual mechanism of a natural CaMKII inhibitor.

Authors:  Rebekah S Vest; Kurtis D Davies; Heather O'Leary; J David Port; K Ulrich Bayer
Journal:  Mol Biol Cell       Date:  2007-10-17       Impact factor: 4.138

10.  Autophosphorylated calcium/calmodulin-dependent protein kinase II alpha (CaMKII alpha) reversibly targets to and phosphorylates N-methyl-D-aspartate receptor subunit 2B (NR2B) in cerebral ischemia and reperfusion in hippocampus of rats.

Authors:  Fanjie Meng; Jun Guo; Quanguang Zhang; Bo Song; Guangyi Zhang
Journal:  Brain Res       Date:  2003-03-28       Impact factor: 3.252

View more
  12 in total

1.  Rbfox-1 contributes to CaMKIIα expression and intracerebral hemorrhage-induced secondary brain injury via blocking micro-RNA-124.

Authors:  Fang Shen; Xiang Xu; Zhengquan Yu; Haiying Li; Haitao Shen; Xiang Li; Meifen Shen; Gang Chen
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-04       Impact factor: 6.200

2.  Photobiomodulation Therapy Attenuates Hypoxic-Ischemic Injury in a Neonatal Rat Model.

Authors:  Lorelei Donovan Tucker; Yujiao Lu; Yan Dong; Luodan Yang; Yong Li; Ningjun Zhao; Quanguang Zhang
Journal:  J Mol Neurosci       Date:  2018-07-22       Impact factor: 3.444

3.  Calcium/Calmodulin-Dependent Kinase (CaMKII) Inhibition Protects Against Purkinje Cell Damage Following CA/CPR in Mice.

Authors:  Nicholas E Chalmers; Joan Yonchek; Kathryn E Steklac; Matthew Ramsey; K Ulrich Bayer; Paco S Herson; Nidia Quillinan
Journal:  Mol Neurobiol       Date:  2019-09-13       Impact factor: 5.590

4.  Antidepressant-like effects of the Guanxin Danshen formula via mediation of the CaMK II-CREB-BDNF signalling pathway in chronic unpredictable mild stress-induced depressive rats.

Authors:  Weijie Xie; Xiangbao Meng; Yadong Zhai; Tianyuan Ye; Ping Zhou; Fengwei Nan; Guibo Sun; Xiaobo Sun
Journal:  Ann Transl Med       Date:  2019-10

Review 5.  The Calcium/Calmodulin-Dependent Kinases II and IV as Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders.

Authors:  Kinga Sałaciak; Aleksandra Koszałka; Elżbieta Żmudzka; Karolina Pytka
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

6.  Immune Suppression of Glia Maturation Factor Reverses Behavioral Impairment, Attenuates Amyloid Plaque Pathology and Neuroinflammation in an Alzheimer's Disease Mouse Model.

Authors:  Mohammad Ejaz Ahmed; Govindhasamy Pushpavathi Selvakumar; Ramasamy Thangavel; Duraisamy Kempuraj; Sudhanshu P Raikwar; Smita Zaheer; Shankar Iyer; Asgar Zaheer
Journal:  J Neuroimmune Pharmacol       Date:  2020-06-05       Impact factor: 4.147

7.  Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action.

Authors:  Bruno P Meloni; Frank L Mastaglia; Neville W Knuckey
Journal:  Front Neurol       Date:  2020-02-25       Impact factor: 4.003

8.  HMGB1-triggered inflammation inhibition of notoginseng leaf triterpenes against cerebral ischemia and reperfusion injury via MAPK and NF-κB signaling pathways.

Authors:  Weijie Xie; Ting Zhu; Xi Dong; Fengwei Nan; Xiangbao Meng; Ping Zhou; Guibo Sun; Xiaobo Sun
Journal:  Biomolecules       Date:  2019-09-20

Review 9.  Calcium/Calmodulin-Dependent Protein Kinase II in Cerebrovascular Diseases.

Authors:  Xuejing Zhang; Jaclyn Connelly; Edwin S Levitan; Dandan Sun; Jane Q Wang
Journal:  Transl Stroke Res       Date:  2021-03-13       Impact factor: 6.829

10.  GHB analogs confer neuroprotection through specific interaction with the CaMKIIα hub domain.

Authors:  Ulrike Leurs; Anders B Klein; Ethan D McSpadden; Nane Griem-Krey; Sara M Ø Solbak; Josh Houlton; Inge S Villumsen; Stine B Vogensen; Louise Hamborg; Stine J Gauger; Line B Palmelund; Anne Sofie G Larsen; Mohamed A Shehata; Christian D Kelstrup; Jesper V Olsen; Anders Bach; Robert O Burnie; D Steven Kerr; Emma K Gowing; Selina M W Teurlings; Chris C Chi; Christine L Gee; Bente Frølund; Birgitte R Kornum; Geeske M van Woerden; Rasmus P Clausen; John Kuriyan; Andrew N Clarkson; Petrine Wellendorph
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.